Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,14 USD | +0,64% | +3,97% | -31,74% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 32,72 mln. 30,49 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 72,59% |
Recentste transcriptie over NRx Pharmaceuticals, Inc.
1 dag | +0,64% | ||
1 week | +3,97% | ||
Lopende maand | -33,46% | ||
1 maand | -40,75% | ||
3 maanden | -24,90% | ||
6 maanden | +19,66% | ||
Lopend jaar | -31,74% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Willard
CEO | Chief Executive Officer | 63 | 12-07-22 |
Jonathan Javitt
FOU | Founder | 67 | 18-09-17 |
Richard Narido
DFI | Director of Finance/CFO | 46 | 13-09-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jonathan Javitt
FOU | Founder | 67 | 18-09-17 |
Stephen Willard
CEO | Chief Executive Officer | 63 | 12-07-22 |
Janet Rehnquist
BRD | Director/Board Member | - | 27/12 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
25-04-24 | 3,14 | +0,64% | 102 032 |
24-04-24 | 3,12 | +2,30% | 97 946 |
23-04-24 | 3,05 | +1,67% | 106 468 |
22-04-24 | 3 | -1,32% | 211 625 |
19-04-24 | 3,04 | +0,66% | 233 600 |
uitgestelde koers Nasdaq, 25 april 2024 om 22:00 uur
Meer koersenKwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-31,74% | 32,72 mln. | |
+1,12% | 42,59 mld. | |
+6,77% | 40,65 mld. | |
+45,26% | 40,57 mld. | |
-11,96% | 26,77 mld. | |
+6,01% | 24,81 mld. | |
-24,92% | 18,17 mld. | |
-3,63% | 11,7 mld. | |
+27,16% | 12,05 mld. | |
+7,30% | 11,1 mld. |